Compass Pathways (NASDAQ:CMPS) Upgraded by Wall Street Zen to Sell Rating

Key Points

• Wall Street Zen upgraded Compass Pathways from “strong sell” to “sell,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $23.36.
• Compass Pathways shares opened at $13.51, with a $1.87 billion market capitalization and a 52-week range of $4.40 to $15.40.
• The clinical-stage biotechnology company reported a quarterly loss of $1.88 per share, missing the consensus estimate of a $0.39 loss; analysts expect a full-year loss of $1.26 per share.

Compass Pathways (NASDAQ:CMPS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued on Tuesday, Wall Street Zen reports.

CMPS has been the subject of a number of other research reports. Wells Fargo & Company began coverage on Compass Pathways in a research note on Monday, July 27th. They issued an "equal weight" rating and a $13.00 price target for the company. BTIG Research raised their target price on shares of Compass Pathways from $14.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, July 7th. Wolfe Research reiterated an "outperform" rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Evercore upgraded shares of Compass Pathways from an "in-line" rating to an "outperform" rating and set a $21.00 price target for the company in a research report on Wednesday, July 8th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Compass Pathways in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.36.

Compass Pathways Price Performance

Compass Pathways stock opened at $13.51 on Tuesday. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -2.92 and a beta of 2.50. The firm has a 50 day moving average price of $13.11 and a 200 day moving average price of $10.16. Compass Pathways has a 1 year low of $4.40 and a 1 year high of $15.40. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Sell-side analysts predict that Compass Pathways will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock valued at $26,000 after buying an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the 4th quarter valued at $38,000. Parallel Advisors LLC lifted its holdings in Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company's stock valued at $40,000 after purchasing an additional 7,183 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Compass Pathways in the third quarter valued at approximately $41,000. Finally, North Star Investment Management Corp. boosted its stake in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company's stock worth $42,000 after purchasing an additional 7,000 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

About Compass Pathways

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source